Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating two dosing regimens of adalimumab in moderate to severe ulcerative colitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie | Conditions: Ulcerative Colitis (UC) | Phase 3 | Status: COMPLETED | Results posted: 2020-10-08